Positive Phase 3 results for vilazodone


Forest Labs (FRX +1.9%) reports top line results from three Phase 3 clinical trials evaluating the safety, efficacy and tolerability of vilazodone in adult patients with generalized anxiety disorder (GAD). In all three studies, patients receiving vilazodone demonstrated statistically significant improvements as measured by the Hamilton Rating Scale for Anxiety total score versus placebo.

The company expects to file a sNDA for the label expansion in 2015.

Comments (2)
  • Chris DeMuth Jr.
    , contributor
    Comments (10607) | Send Message
     
    "• The company expects to file an ANDA for a generic version of the branded product in 2015."

     

    Where did Seeking Alpha get that information? Not from the press release that this summary linked to.
    23 Jun 2014, 04:43 PM Reply Like
  • Joe McCann
    , contributor
    Comments (257) | Send Message
     
    I think SA means an sNDA for the additional indication on the label. aNDA's are for generic drugs, sNDAs are to broaden a label etc.
    23 Jun 2014, 05:05 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs